Non-Small Cell Lung Cancer
Advertisement
The trial is the first to evaluate the investigational telomere-targeting agent with a PD-(L)1 inhibitior.
Study investigators say that extended follow-up research on nivolumab consolidation is essential.
The initiative aims to increase biomarker testing rates in communities most impacted by lung cancer disparities.
Dr. Paz-Ares shares his insights on the study's results and the remaining questions about ADCs in lung cancer treatment.
The CheckMate 9LA study evaluated first-line nivolumab plus ipilimumab with 2 cycles of platinum-doublet chemotherapy.
A researcher discusses the implications of identifying potentially pathogenic bacteria in adenocarcinoma tumors.
The study showed that the detection of ctDNA predicted significantly inferior NSCLC.
Valsamo Anagnostou, MD, PhD, discusses advances in the field and her lab's research on the topic.
The drug combination showed "reduced efficacy" in terms of PFS and OS, officials said.
IDE397, a “potential first-in-class” MAT2A inhibitor, is under evaluation in phase 2 clinical trials.
Researchers compared outcomes between patients with baseline stage III N2 and non-N2 NSCLC.
The European Commission’s approval is based on results from the phase 3 FLAURA2 trial.
Most patients who received adjuvant osimertinib achieved MRD negativity.
Researchers assessed patients' functional health and well-being across multiple physical and mental domains.
The approval is based upon results from the phase 3 FLAURA2 trial and a subgroup analysis of a cohort from China.
Laila Gharzai, MD, discusses her research on the financial impacts of lung biomarker testing.
Dr. Mehta discusses the study, which met its primary end point, and future directions for the research.
A prospective study evaluated if hypercoagulable and inflammatory biomarkers could predict certain outcomes.
Samantha Armstrong, MD, and Karine Tawagi, MD, discuss the interview on the groundbreaking plenary presentation.
An analysis of the phase 3 trial evaluated multiple aspects of health-related quality of life.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.